Chuangsheng Group-B (06628) announced at AACR 2025 the new antibody-drug conjugate (ADC) targeting FGFR2b and topo-isomerase I inhibitor payload showed promising anti-tumor activity in preclinical tumor models.

Zhtng cijng APP xn, chung shng jtun-B (06628) fb gnggo, gngs y 2025 nin Migu i'n ynji xihu ninhu (AACR 2025) shng gngble jy xnxng rnyun hu FGFR2b kngti shub de ADC (TST105) de zuxn lnghu ynji jigu. Gi ADC ciyng tngj zhunyngzhn jido de dngdin ulin jsh, di zi xnxng tup ygu mng II ufzhzh zuwi xioli, zi lnghu q i h jizh xing cnci mxng zhng, xing b y MMAE wi zuwi de ADC, zhnxin ch xingubi de kngzhng huxng.